| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LTB |
| Uniprot No | Q14767 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1821aa |
| 氨基酸序列 | MRPRTKARSPGRALRNPWRGFLPLTLALFVGAGHAQRDPVGRYEPAGGDANRLRRPGGSYPAAAAAKVYSLFREQDAPVAGLQPVERAQPGWGSPRRPTEAEARRPSRAQQSRRVQPPAQTRRSTPLGQQQPAPRTRAAPALPRLGTPQRSGAAPPTPPRGRLTGRNVCGGQCCPGWTTANSTNHCIKPVCEPPCQNRGSCSRPQLCVCRSGFRGARCEEVIPDEEFDPQNSRLAPRRWAERSPNLRRSSAAGEGTLARAQPPAPQSPPAPQSPPAGTLSGLSQTHPSQQHVGLSRTVRLHPTATASSQLSSNALPPGPGLEQRDGTQQAVPLEHPSSPWGLNLTEKIKKIKIVFTPTICKQTCARGHCANSCERGDTTTLYSQGGHGHDPKSGFRIYFCQIPCLNGGRCIGRDECWCPANSTGKFCHLPIPQPDREPPGRGSRPRALLEAPLKQSTFTLPLSNQLASVNPSLVKVHIHHPPEASVQIHQVAQVRGGVEEALVENSVETRPPPWLPASPGHSLWDSNNIPARSGEPPRPLPPAAPRPRGLLGRCYLNTVNGQCANPLLELTTQEDCCGSVGAFWGVTLCAPCPPRPASPVIENGQLECPQGYKRLNLTHCQDINECLTLGLCKDAECVNTRGSYLCTCRPGLMLDPSRSRCVSDKAISMLQGLCYRSLGPGTCTLPLAQRITKQICCCSRVGKAWGSECEKCPLPGTEAFREICPAGHGYTYASSDIRLSMRKAEEEELARPPREQGQRSSGALPGPAERQPLRVVTDTWLEAGTIPDKGDSQAGQVTTSVTHAPAWVTGNATTPPMPEQGIAEIQEEQVTPSTDVLVTLSTPGIDRCAAGATNVCGPGTCVNLPDGYRCVCSPGYQLHPSQAYCTDDNECLRDPCKGKGRCINRVGSYSCFCYPGYTLATSGATQECQDINECEQPGVCSGGQCTNTEGSYHCECDQGYIMVRKGHCQDINECRHPGTCPDGRCVNSPGSYTCLACEEGYRGQSGSCVDVNECLTPGVCAHGKCTNLEGSFRCSCEQGYEVTSDEKGCQDVDECASRASCPTGLCLNTEGSFACSACENGYWVNEDGTACEDLDECAFPGVCPSGVCTNTAGSFSCKDCDGGYRPSPLGDSCEDVDECEDPQSSCLGGECKNTVGSYQCLCPQGFQLANGTVCEDVNECMGEEHCAPHGECLNSHGSFFCLCAPGFVSAEGGTSCQDVDECATTDPCVGGHCVNTEGSFNCLCETGFQPSPESGECVDIDECEDYGDPVCGTWKCENSPGSYRCVLGCQPGFHMAPNGDCIDIDECANDTMCGSHGFCDNTDGSFRCLCDQGFEISPSGWDCVDVNECELMLAVCGAALCENVEGSFLCLCASDLEEYDAQEGHCRPRGAGGQSMSEAPTGDHAPAPTRMDCYSGQKGHAPCSSVLGRNTTQAECCCTQGASWGDACDLCPSEDSAEFSEICPSGKGYIPVEGAWTFGQTMYTDADECVIFGPGLCPNGRCLNTVPGYVCLCNPGFHYDASHKKCEDHDECQDLACENGECVNTEGSFHCFCSPPLTLDLSQQRCMNSTSSTEDLPDHDIHMDICWKKVTNDVCSEPLRGHRTTYTECCCQDGEAWSQQCALCPPRSSEVYAQLCNVARIEAEREAGVHFRPGYEYGPGPDDLHYSIYGPDGAPFYNYLGPEDTVPEPAFPNTAGHSADRTPILESPLQPSELQPHYVASHPEPPAGFEGLQAEECGILNGCENGRCVRVREGYTCDCFEGFQLDAAHMACVDVNECDDLNGPAVLCVHGYCENTEGSYRCHCSPGYVAEAGPPHCTAKE |
| 预测分子量 | 195 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LTB(热不稳定肠毒素B亚基)重组蛋白的3篇假设性参考文献示例，格式为文献名称、作者及摘要概括：
1. **《Expression and purification of recombinant LTB protein for mucosal vaccine development》**
- 作者：Zhang Y, Li H, Wang X
- 摘要：研究通过大肠杆菌表达系统高效表达LTB重组蛋白，优化纯化工艺获得高纯度产物，并验证其结合GM1神经节苷脂受体的能力，表明其可作为黏膜疫苗载体。
2. **《Enhancing antigen-specific immune responses using LTB as a molecular adjuvant in fusion proteins》**
- 作者：Xu J, Chen T, Liu R
- 摘要：将LTB与流感病毒抗原融合表达，证明重组蛋白可显著增强小鼠黏膜IgA及血清IgG抗体水平，证实LTB的佐剂功能及靶向递送潜力。
3. **《Oral immunization with LTB-rotavirus VP6 recombinant protein induces protective immunity in mice》**
- 作者：Chen L, Martinez-Sobrido L, García-Sastre A
- 摘要：构建轮状病毒VP6与LTB的融合蛋白，口服免疫小鼠后引发黏膜和系统免疫应答，降低病毒载量，为口服疫苗设计提供新策略。
(注：以上文献为示例，实际引用需以真实发表论文为准。)
**Background of LTB Recombinant Protein**
The **heat-labile enterotoxin B subunit (LTB)**, derived from *Escherichia coli*, is a non-toxic protein component widely studied for its immunomodulatory properties and biotechnological applications. LTB forms a pentameric structure that binds specifically to GM1 ganglioside receptors on eukaryotic cells, a mechanism originally associated with the toxin’s role in facilitating bacterial adhesion and toxin delivery. However, recombinant LTB, produced via genetic engineering in bacterial (e.g., *E. coli*) or eukaryotic expression systems, lacks the toxic A subunit, making it safe for biomedical use.
LTB gained prominence as a mucosal adjuvant due to its ability to enhance immune responses to co-administered antigens, particularly in oral or intranasal vaccines. Its GM1-binding property promotes antigen uptake by mucosal dendritic cells, stimulating both systemic and mucosal immunity—critical for combating pathogens entering through mucosal surfaces. This feature has driven its inclusion in vaccine candidates targeting enteric diseases (e.g., cholera, enterotoxigenic *E. coli*), as well as non-infectious conditions like autoimmune disorders.
Recombinant LTB production leverages scalable fermentation techniques, ensuring high yield and purity. Its stability and cost-effectiveness further support industrial applications. Beyond vaccines, LTB serves as a tool in neuroscience for tracing neuronal pathways via GM1 receptor targeting and in drug delivery systems to enhance macromolecule transport across epithelial barriers.
Recent research explores its potential in cancer immunotherapy and as a carrier for antigen fusion proteins, capitalizing on its self-assembling structure. Safety studies confirm minimal toxicity, underscoring its versatility in therapeutic and diagnostic platforms. Overall, LTB exemplifies how bacterial protein engineering can bridge microbiology and translational medicine, offering solutions to global health challenges.
×
